Cidara Therapeutics, Inc.
US ˙ NasdaqCM ˙ US1717571079

Introduction

This page provides a comprehensive analysis of the known insider trading history of Marc Wilson. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Marc Wilson has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CRNX / Crinetics Pharmaceuticals, Inc. CFO 111,565
US:CDTX / Cidara Therapeutics, Inc. Chief Accounting Officer 10,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Marc Wilson. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CDTX / Cidara Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CDTX / Cidara Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CDTX / Cidara Therapeutics, Inc. Insider Trades
Insider Sales CDTX / Cidara Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CDTX / Cidara Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CDTX / Cidara Therapeutics, Inc. Insider Trades
Insider Purchases CRNX / Crinetics Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CDTX / Cidara Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CRNX / Crinetics Pharmaceuticals, Inc. Insider Trades
Insider Sales CRNX / Crinetics Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CDTX / Cidara Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2023-11-01 CRNX Wilson Marc 10,000 28.7500 10,000 28.7500 287,500 8 26.6900 -20,600 -7.17
2023-06-20 CRNX Wilson Marc 10,922 19.9600 10,922 19.9600 218,003
2023-06-20 CRNX Wilson Marc 20,000 19.9700 20,000 19.9700 399,400

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CRNX / Crinetics Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Marc Wilson as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2025-01-29 2024-11-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		J - Other 473 111,565 0.43 14.98 7,086 1,671,244
2024-09-30 2024-09-26 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		S - Sale X -25,000 111,092 -18.37 51.11 -1,277,750 5,677,912
2024-09-30 2024-09-26 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		M - Exercise 25,000 136,092 22.50 15.29 382,250 2,080,847
2024-07-26 2024-07-25 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		S - Sale X -19,056 111,092 -14.64 53.88 -1,026,737 5,985,637
2024-07-26 2024-07-25 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		M - Exercise 19,056 130,148 17.15 9.28 176,840 1,207,773
2024-07-17 2024-07-15 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		S - Sale X -25,000 111,092 -18.37 55.00 -1,375,000 6,110,060
2024-07-17 2024-07-15 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		M - Exercise 25,000 136,092 22.50 20.02 500,500 2,724,562
2024-07-02 2024-06-28 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		S - Sale X -32,129 111,092 -22.43 43.61 -1,401,146 4,844,722
2024-07-02 2024-06-28 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		M - Exercise 32,129 143,221 28.92 9.28 298,157 1,329,091
2024-03-20 2024-03-19 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		S - Sale X -6,942 110,630 -5.90 42.91 -297,881 4,747,133
2024-03-20 2024-03-18 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		F - Taxes X -3,983 117,572 -3.28 38.14 -151,912 4,484,196
2024-03-06 2024-03-04 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		A - Award 25,500 121,555 26.55
2024-01-04 2024-01-02 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		S - Sale X -10,000 96,055 -9.43 35.47 -354,700 3,407,071
2024-01-04 2024-01-02 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		M - Exercise 10,000 106,055 10.41 9.28 92,800 984,190
2023-11-03 2023-11-01 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		S - Sale -10,000 95,601 -9.47 28.75 -287,500 2,748,529
2023-11-03 2023-11-01 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		M - Exercise 10,000 105,601 10.46 9.28 92,800 979,977
2023-06-21 2023-06-20 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		S - Sale -20,000 95,158 -17.37 19.97 -399,400 1,900,305
2023-06-21 2023-06-20 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		M - Exercise 20,000 115,158 21.02 9.28 185,600 1,068,666
2023-06-21 2023-06-20 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		S - Sale -10,922 95,158 -10.30 19.96 -218,003 1,899,354
2023-03-17 2023-03-16 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		F - Taxes X -1,666 106,080 -1.55 17.12 -28,522 1,816,090
2023-03-03 2023-03-01 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		A - Award 24,200 107,746 28.97
2023-01-27 2022-11-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		J - Other 482 83,546 0.58 11.02 5,312 920,677
2023-01-27 2022-05-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		J - Other 1,446 83,064 1.77 11.02 15,935 915,365
2022-03-02 2022-02-28 4 CRNX Crinetics Pharmaceuticals, Inc.
Stock Option (right to buy) 		A - Award 91,000 91,000
2022-03-02 2022-02-28 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		A - Award 19,500 81,618 31.39
2022-02-04 2021-11-19 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		J - Other 837 62,118 1.37 11.02 9,224 684,540
2022-02-04 2021-05-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		J - Other 1,090 61,281 1.81 11.02 12,012 675,317
2021-03-02 2021-02-26 4 CRNX Crinetics Pharmaceuticals, Inc.
Stock Option (right to buy) 		A - Award 114,000 114,000
2021-02-05 2020-11-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		J - Other 702 60,191 1.18 11.61 8,150 698,818
2021-02-05 2020-05-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		J - Other 697 59,489 1.19 14.45 10,072 859,616
2020-02-26 2020-02-24 4 CRNX Crinetics Pharmaceuticals, Inc.
Stock Option (right to buy) 		A - Award 70,000 70,000
2020-02-11 2019-05-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		J - Other 1,471 58,792 2.57 14.45 21,256 849,544
2019-03-12 2019-03-08 4 CRNX Crinetics Pharmaceuticals, Inc.
Stock Option (right to buy) 		A - Award 56,250 56,250
2019-02-12 2018-11-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		J - Other 1,470 57,321 2.63 14.45 21,242 828,288
2018-07-17 3 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		111,702
2018-07-17 3 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		111,702
2018-07-17 3 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock 		111,702
2017-09-19 2017-09-18 4 CDTX Cidara Therapeutics, Inc.
Restricted Stock Unit 		M - Exercise 10,000 10,000
2017-09-19 2017-09-18 4 CDTX Cidara Therapeutics, Inc.
Common Stock 		A - Award 5,000 10,356 93.35
2017-04-04 2017-03-31 4 CDTX Cidara Therapeutics, Inc.
Employee Stock Option (right to buy) 		A - Award 25,000 25,000
2017-04-04 2016-03-16 4 CDTX Cidara Therapeutics, Inc.
Employee Stock Option (right to buy) 		A - Award 12,000 12,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)